Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04241185
Registration number
NCT04241185
Ethics application status
Date submitted
22/01/2020
Date registered
27/01/2020
Date last updated
10/05/2024
Titles & IDs
Public title
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Query!
Scientific title
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
Query!
Secondary ID [1]
0
0
MK-3475-992
Query!
Secondary ID [2]
0
0
3475-992
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Urinary Bladder Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bladder - transitional cell cancer
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Pembrolizumab
Treatment: Other - Conventional Radiotherapy (Bladder only)
Treatment: Other - Conventional Radiotherapy (Bladder and pelvic nodes)
Treatment: Other - Hypofractionated Radiotherapy (Bladder only)
Treatment: Drugs - Cisplatin
Treatment: Drugs - Fluorouracil (5-FU)
Treatment: Drugs - Mitomycin C (MMC)
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Placebo to Pembrolizumab
Experimental: Pembrolizumab + Chemotherapy + Radiotherapy - Participants receive pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
Placebo Comparator: Placebo + Chemotherapy + Radiotherapy - Participants receive placebo to pembrolizumab plus one of three chemotherapy regimens chosen by investigator, plus one of three radiotherapy regimens chosen by investigator.
Treatment: Drugs: Pembrolizumab
400 mg of IV (intravenous) pembrolizumab once every 6 weeks.
Treatment: Other: Conventional Radiotherapy (Bladder only)
64 Gy of radiation administered to participant's bladder only. Thirty-two fractions will be administered over 6.5 weeks.
Treatment: Other: Conventional Radiotherapy (Bladder and pelvic nodes)
64 Gy of radiation administered to participant's bladder and pelvic nodes. Thirty-two fractions will be administered over 6.5 weeks.
Treatment: Other: Hypofractionated Radiotherapy (Bladder only)
55 Gy of radiation administered to participant's bladder only. Twenty fractions will be administered over 4 weeks.
Treatment: Drugs: Cisplatin
35 mg of cisplatin per cubic meter of body volume, administered once weekly via IV infusion.
Treatment: Drugs: Fluorouracil (5-FU)
5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
Treatment: Drugs: Mitomycin C (MMC)
MMC administered via IV infusion at a dose of 12 mg per cubic meter of body volume on Day 1.
Treatment: Drugs: Gemcitabine
Gemcitabine administered via IV infusion at a dose of 27 mg per cubic meter of body volume twice weekly.
Treatment: Drugs: Placebo to Pembrolizumab
Placebo to intravenous (IV) pembrolizumab administered once every 6 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Bladder Intact Event-Free Survival (BI-EFS)
Query!
Assessment method [1]
0
0
BI-EFS is defined as the time from randomization to any of the following events: residual/recurrent MIBC post-chemoradiotherapy (CRT), nodal or distant metastases as assessed by computerized tomography (CT) and CT urography (CTU) or magnetic resonance urography (MRU) per blinded independent central review (BICR) and/or biopsy results assessed by central pathology review, radical cystectomy, or death due to any cause. If biopsy is not feasible due to participant safety, the imaging alone will be sufficient. The BI-EFS for all participants will be presented.
Query!
Timepoint [1]
0
0
Up to approximately 71 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Time from randomization to death due to any cause.
Query!
Timepoint [1]
0
0
Up to approximately 83 months
Query!
Secondary outcome [2]
0
0
Metastasis-Free Survival (MFS)
Query!
Assessment method [2]
0
0
MFS is defined as the time from randomization to the first documented occurrence of nodal or distant metastases as assessed by CT and CTU or MRU per BICR and/or biopsy results assessed by central pathology review If biopsy is not feasible due to participant safety, the imaging alone will be sufficient.
Query!
Timepoint [2]
0
0
Up to approximately 83 months
Query!
Secondary outcome [3]
0
0
Time to Occurrence of Non-Muscle-Invasive Bladder Cancer (NMIBC)
Query!
Assessment method [3]
0
0
Time to occurrence of low-grade disease, defined as the time from randomization until the development of NMIBC, will be presented.
Query!
Timepoint [3]
0
0
Up to approximately 83 months
Query!
Secondary outcome [4]
0
0
Number of Participants Who Experienced an Adverse Event (AE)
Query!
Assessment method [4]
0
0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.
Query!
Timepoint [4]
0
0
Up to approximately 83 months
Query!
Secondary outcome [5]
0
0
Number of Participants Who Discontinued Study Intervention Due to an AE
Query!
Assessment method [5]
0
0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.
Query!
Timepoint [5]
0
0
Up to approximately 1 year
Query!
Secondary outcome [6]
0
0
Change from Baseline in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Query!
Assessment method [6]
0
0
The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. The change from baseline in Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented.
Query!
Timepoint [6]
0
0
Baseline and up to approximately 83 months
Query!
Secondary outcome [7]
0
0
Change from Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30
Query!
Assessment method [7]
0
0
EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented.
Query!
Timepoint [7]
0
0
Baseline and up to approximately 83 months
Query!
Secondary outcome [8]
0
0
Change from Baseline in Urinary, Bowel, and Sexual Domains of the Bladder Cancer Index (BCI)
Query!
Assessment method [8]
0
0
The BCI is a validated, condition-specific health questionnaire assessing quality of life among participants with bladder cancer. The BCI contains 36 items which assess 3 domains (urinary, bowel, and sexual) with function and bother subdomains. Scores range from 0 to 100 with higher scores corresponding to better functioning and health-related quality of life. The change from baseline in the combined scores of the urinary, bowel, and sexual domains of the BCI will be presented.
Query!
Timepoint [8]
0
0
Baseline and up to approximately 83 months
Query!
Secondary outcome [9]
0
0
Change from Baseline in the Visual Analog Score (VAS) of the European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L)
Query!
Assessment method [9]
0
0
The EQ-5D-5L VAS records the respondent's self-rated health on a 10 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being "the worst health you can imagine" and 100 being "the best health you can imagine". The change from baseline in EQ-5D-5L VAS will be presented.
Query!
Timepoint [9]
0
0
Baseline and up to approximately 83 months
Query!
Secondary outcome [10]
0
0
Time to Deterioration (TTD) in the Global Health Status/Quality of Life (Items 29 and 30) Combined Score on the EORTC QLQ-C30
Query!
Assessment method [10]
0
0
The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1=Very Poor to 7=Excellent). A higher score indicates a better overall outcome. TTD in Global Health Status/Quality of Life is defined as the time from baseline to the first onset of a 10 point or greater decrease from baseline in the Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score, with or without subsequent confirmation.
Query!
Timepoint [10]
0
0
Up to approximately 83 months
Query!
Secondary outcome [11]
0
0
TTD in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30
Query!
Assessment method [11]
0
0
EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a better quality of life. TTD in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score is defined as the time from baseline (at randomization) to the first onset of a =10-point decrease with confirmation by the subsequent visit of a =10-point decrease in physical functioning Items 1 to 5 scale scores.
Query!
Timepoint [11]
0
0
Up to approximately 83 months
Query!
Secondary outcome [12]
0
0
TTD in Urinary, Bowel, and Sexual Domains of the BCI
Query!
Assessment method [12]
0
0
The BCI is a validated, condition-specific health questionnaire assessing quality of life among participants with bladder cancer. The BCI contains 36 items which assess 3 domains (urinary, bowel, and sexual) with function and bother subdomains. Scores range from 0 to 100 with higher scores corresponding to better functioning and health-related quality of life. TTD in BCI is defined as a 6, 7, and 7 points or greater worsening from baseline for urinary, bowel, and sexual domains, respectively, with or without subsequent confirmation, under a right-censoring rule.
Query!
Timepoint [12]
0
0
Up to approximately 83 months
Query!
Secondary outcome [13]
0
0
TTD in the VAS of the EQ-5D-5L
Query!
Assessment method [13]
0
0
The EQ-5D-5L VAS records the respondent's self-rated health on a 10 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being "the worst health you can imagine" and 100 being "the best health you can imagine". TTD in EQ-5D-5L VAS is defined as the time from baseline to the first onset of a 7 point or greater decrease from baseline in EQ-5D-5L VAS, with or without subsequent confirmation, under a right-censoring rule.
Query!
Timepoint [13]
0
0
Up to approximately 83 months
Query!
Secondary outcome [14]
0
0
Time to Cystectomy
Query!
Assessment method [14]
0
0
Time to cystectomy is defined as time from a participant's randomization to date of cystectomy.
Query!
Timepoint [14]
0
0
Up to approximately 83 months
Query!
Eligibility
Key inclusion criteria
- Has a histologically confirmed initial diagnosis of muscle-invasive bladder cancer
(MIBC) with predominant urothelial histology
- Has clinically nonmetastatic bladder cancer (N0M0)
- Has planned and is eligible to receive chemoradiotherapy (CRT) and one of the
protocol-specified radiosensitizing chemotherapy regimens
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Demonstrates adequate organ function
- Male participants are eligible to participate if they agree to the following during
the intervention period and for at least 90 days after the last dose of CRT treatment:
- Refrain from donating sperm
- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle
(abstinent on a long term and persistent basis) and agree to remain abstinent; or
must agree to use contraception unless confirmed to be azoospermic
- A female participant is eligible to participate if she is not pregnant or
breastfeeding, and at least one of the following conditions applies:
- Is not a woman of childbearing potential (WOCBP)
- Is a WOCBP and using a contraceptive method that is highly effective (with a
failure rate of <1% per year), with low user dependency or be abstinent from
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a
long term and persistent basis), during the intervention period and for at least
180 days the time needed to eliminate each study intervention after the last dose
of study intervention; and agrees not to donate eggs (ova, oocytes) to others or
freeze/store for her own use for the purpose of reproduction during this period.
The length of time required to continue contraception for each study intervention
is as follows: MK-3475 - 120 days and CRT - 180 days
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has the presence of diffuse carcinoma in situ (CIS) (multiple foci of CIS) throughout
the bladder
- Has the presence of urothelial carcinoma (UC) at any site outside of the urinary
bladder in the previous 2 years except for Ta stage/T1 stage/CIS of the upper tract if
the participant has undergone a complete nephroureterectomy
- Has a known additional malignancy that is progressing or has required active therapy
within the past 3 years, except basal cell carcinoma of the skin, squamous cell
carcinoma of the skin, superficial bladder cancer or other carcinoma in situ that has
undergone potentially curative therapy
- Has the presence of bilateral hydronephrosis
- Has limited bladder function with frequency of small amounts of urine (< 30 mL),
urinary incontinence, or requires self-catheterization or a permanent indwelling
catheter
- Has received prior pelvic/local radiation therapy or any antineoplastic treatment for
muscle-invasive bladder cancer (MIBC). Treatment for non-muscle invasive bladder
cancer (NMIBC) with intravesical instillation therapy that was completed =28 days
prior to randomization is allowed. Prior systemic treatment of NMIBC is not permitted.
- Received prior therapy with an anti-PD-1 (programmed cell death protein 1), anti-PD-L1
(programmed death-ligand 1), or anti-PD-L2 (programmed cell death 1 ligand 2), or with
an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., CTLA-4
[cytotoxic T-lymphocyte-associated protein 4], OX 40, or CD137 [cluster of
differentiation 137])
- Has received a live vaccine within 30 days before the first dose of study medication
- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks before the first dose of
study medication
- Has known severe hypersensitivity (=Grade 3) to the selected chemotherapy regimen,
and/or any of their excipients and excipients of pembrolizumab
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days before the first dose of study medication
- Has an active autoimmune disease that has required systemic treatment in the past 2
years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency) is not considered a form
of systemic treatment and is allowed
- Has a history of non-infectious pneumonitis that required steroids or has current
pneumonitis
- Has an active infection requiring systemic therapy
- Has a known history of human immunodeficiency virus (HIV) infection
- Has a known history of hepatitis B or known active hepatitis C virus infection
- Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
- Has a known psychiatric or substance abuse disorder that would interfere with the
participant's ability to cooperate with the requirements of the study
- Has had an allogenic tissue/solid organ transplant
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/05/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
10/06/2031
Query!
Actual
Query!
Sample size
Target
636
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
Liverpool Hospital ( Site 0220) - Liverpool
Query!
Recruitment hospital [2]
0
0
GenesisCare North Shore ( Site 0217) - St Leonards
Query!
Recruitment hospital [3]
0
0
Monash Medical Centre ( Site 0216) - Clayton
Query!
Recruitment hospital [4]
0
0
Austin Health ( Site 0218) - Heidelberg
Query!
Recruitment hospital [5]
0
0
Sir Charles Gairdner Hospital ( Site 0223) - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
District of Columbia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kentucky
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New Jersey
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Virginia
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
West Virginia
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Wisconsin
Query!
Country [15]
0
0
Chile
Query!
State/province [15]
0
0
Los Rios
Query!
Country [16]
0
0
Chile
Query!
State/province [16]
0
0
Region M. De Santiago
Query!
Country [17]
0
0
Chile
Query!
State/province [17]
0
0
Valparaiso
Query!
Country [18]
0
0
Chile
Query!
State/province [18]
0
0
Antofagasta
Query!
Country [19]
0
0
Czechia
Query!
State/province [19]
0
0
Olomouc
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Praha 5
Query!
Country [21]
0
0
Czechia
Query!
State/province [21]
0
0
Praha 8
Query!
Country [22]
0
0
Denmark
Query!
State/province [22]
0
0
Hovedstaden
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Syddanmark
Query!
Country [24]
0
0
Estonia
Query!
State/province [24]
0
0
Harjumaa
Query!
Country [25]
0
0
Estonia
Query!
State/province [25]
0
0
Tartumaa
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Provence-Alpes-Cote-d Azur
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Somme
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Paris
Query!
Country [29]
0
0
Guatemala
Query!
State/province [29]
0
0
Guatemala
Query!
Country [30]
0
0
Guatemala
Query!
State/province [30]
0
0
Quetzaltenango
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Bacs-Kiskun
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Borsod-Abauj-Zemplen
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Gyor-Moson-Sopron
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Debrecen
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Kaposvar
Query!
Country [36]
0
0
Israel
Query!
State/province [36]
0
0
Be'er Sheva
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Haifa
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Jerusalem
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Petah Tikva
Query!
Country [40]
0
0
Israel
Query!
State/province [40]
0
0
Ramat Gan
Query!
Country [41]
0
0
Israel
Query!
State/province [41]
0
0
Tel Aviv
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Lazio
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Lombardia
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Puglia
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Firenze
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Macerata
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Milano
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Modena
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Napoli
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Aomori
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Ibaraki
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Osaka
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Nagasaki
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Tokyo
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Kyonggi-do
Query!
Country [56]
0
0
Korea, Republic of
Query!
State/province [56]
0
0
Seoul
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Taejon-Kwangyokshi
Query!
Country [58]
0
0
Latvia
Query!
State/province [58]
0
0
Riga
Query!
Country [59]
0
0
Malaysia
Query!
State/province [59]
0
0
Kelantan
Query!
Country [60]
0
0
Malaysia
Query!
State/province [60]
0
0
Pulau Pinang
Query!
Country [61]
0
0
Malaysia
Query!
State/province [61]
0
0
Kuala Lumpur
Query!
Country [62]
0
0
Netherlands
Query!
State/province [62]
0
0
Noord-Holland
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
Zuid-Holland
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Malopolskie
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Mazowieckie
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Zachodniopomorskie
Query!
Country [67]
0
0
Portugal
Query!
State/province [67]
0
0
Lisboa
Query!
Country [68]
0
0
Portugal
Query!
State/province [68]
0
0
Coimbra
Query!
Country [69]
0
0
Puerto Rico
Query!
State/province [69]
0
0
Ponce
Query!
Country [70]
0
0
Puerto Rico
Query!
State/province [70]
0
0
San Juan, Rio Piedras
Query!
Country [71]
0
0
Romania
Query!
State/province [71]
0
0
Cluj
Query!
Country [72]
0
0
Romania
Query!
State/province [72]
0
0
Dolj
Query!
Country [73]
0
0
Romania
Query!
State/province [73]
0
0
Timis
Query!
Country [74]
0
0
Romania
Query!
State/province [74]
0
0
Bucuresti
Query!
Country [75]
0
0
Romania
Query!
State/province [75]
0
0
Iasi
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Barcelona
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Valenciana, Comunitat
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Sevilla
Query!
Country [79]
0
0
Taiwan
Query!
State/province [79]
0
0
Tainan
Query!
Country [80]
0
0
Taiwan
Query!
State/province [80]
0
0
Kaohsiung
Query!
Country [81]
0
0
Taiwan
Query!
State/province [81]
0
0
Taichung
Query!
Country [82]
0
0
Taiwan
Query!
State/province [82]
0
0
Taipei
Query!
Country [83]
0
0
Taiwan
Query!
State/province [83]
0
0
Taoyuan
Query!
Country [84]
0
0
Turkey
Query!
State/province [84]
0
0
Ankara
Query!
Country [85]
0
0
Turkey
Query!
State/province [85]
0
0
Istanbul
Query!
Country [86]
0
0
Turkey
Query!
State/province [86]
0
0
Izmir
Query!
Country [87]
0
0
Turkey
Query!
State/province [87]
0
0
Trabzon
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Dnipropetrovska Oblast
Query!
Country [89]
0
0
Ukraine
Query!
State/province [89]
0
0
Kharkivska Oblast
Query!
Country [90]
0
0
Ukraine
Query!
State/province [90]
0
0
Kirovohradska Oblast
Query!
Country [91]
0
0
Ukraine
Query!
State/province [91]
0
0
Kyivska Oblast
Query!
Country [92]
0
0
Ukraine
Query!
State/province [92]
0
0
Kyiv
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Denbighshire
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Devon
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Lancashire
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
London, City Of
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Nottinghamshire
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Darlington
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to assess the antitumor efficacy and safety of pembrolizumab in
combination with chemoradiotherapy (CRT) versus CRT alone in participants with
muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab +
chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact
event-free survival.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04241185
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Toll Free Number
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-888-577-8839
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04241185
Download to PDF